Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard A Fox

Showing results (121-130 of 158) with videos related to

Pageof 16
Sort By:
Molecular Therapy Oncolytics|February 22, 2021
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cellsTamson V Moore, Gina M Scurti, Matthew DeJong, et al.
Seminars in Oncology|November 16, 2010
Signaling through OX40 enhances antitumor immunityShawn M Jensen, Levi D Maston, Michael J Gough, et al.
Journal for Immunotherapy of Cancer|December 1, 2019
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)Paolo A Ascierto, Carlo Bifulco, Luigi Buonaguro, et al.
Journal for Immunotherapy of Cancer|June 28, 2017
Immunotherapy biomarkers 2016: overcoming the barriersJames L Gulley, Jay A Berzofsky, Marcus O Butler, et al.
Cancer Research|November 2, 2013
OX40 is a potent immune-stimulating target in late-stage cancer patientsBrendan D Curti, Magdalena Kovacsovics-Bankowski, Nicholas Morris, et al.
Cancer|December 2, 2016
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning MeetingJulie E Bauman, Ezra Cohen, Robert L Ferris, et al.
Cancer Immunology, Immunotherapy : CII|November 29, 2022
A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA studyAnn W Silk, Steven J O'Day, Howard L Kaufman, et al.
Current Molecular Medicine|August 20, 2009
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effectsUlf Petrausch, Christian H Poehlein, Shawn M Jensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Intratumoral Plasmid IL12 Expands CD8<sup>+</sup> T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 TherapyMelinda L Telli, Hiroshi Nagata, Irene Wapnir, et al.
Journal of Translational Medicine|July 28, 2023
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Allison Betof Warner, et al.
Pageof 16

Showing results (121-130 of 158) with videos related to

Sort By:
Pageof 16
Molecular Therapy Oncolytics|February 22, 2021
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cellsTamson V Moore, Gina M Scurti, Matthew DeJong, et al.
Seminars in Oncology|November 16, 2010
Signaling through OX40 enhances antitumor immunityShawn M Jensen, Levi D Maston, Michael J Gough, et al.
Journal for Immunotherapy of Cancer|December 1, 2019
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)Paolo A Ascierto, Carlo Bifulco, Luigi Buonaguro, et al.
Journal for Immunotherapy of Cancer|June 28, 2017
Immunotherapy biomarkers 2016: overcoming the barriersJames L Gulley, Jay A Berzofsky, Marcus O Butler, et al.
Cancer Research|November 2, 2013
OX40 is a potent immune-stimulating target in late-stage cancer patientsBrendan D Curti, Magdalena Kovacsovics-Bankowski, Nicholas Morris, et al.
Cancer|December 2, 2016
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning MeetingJulie E Bauman, Ezra Cohen, Robert L Ferris, et al.
Cancer Immunology, Immunotherapy : CII|November 29, 2022
A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA studyAnn W Silk, Steven J O'Day, Howard L Kaufman, et al.
Current Molecular Medicine|August 20, 2009
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effectsUlf Petrausch, Christian H Poehlein, Shawn M Jensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Intratumoral Plasmid IL12 Expands CD8<sup>+</sup> T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 TherapyMelinda L Telli, Hiroshi Nagata, Irene Wapnir, et al.
Journal of Translational Medicine|July 28, 2023
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Allison Betof Warner, et al.
Pageof 16